Simposio- Cáncer de Páncreas: retos y perspectivas futuras (Sesiones III y IV)

The symposium provides a comprehensive overview of the current state of pancreatic cancer research, with a strong emphasis on the molecular mechanisms underlying tumor heterogeneity and therapy resistance. The speakers are recognized experts in their fields, and their presentations are based on recent published data and ongoing clinical trials. The content is highly technical, assuming a solid background in oncology and molecular biology. The discussions on KRAS inhibitors, particularly the challenges of targeting this oncogene and the potential combination strategies, are timely and relevant. The presentations highlight the complexity of pancreatic cancer, including the role of the tumor microenvironment, metabolic factors, and genomic alterations such as extrachromosomal DNA. The symposium also addresses the clinical implications of these findings, with a focus on improving patient outcomes. However, as a symposium, the content is presented in a lecture format, and some presentations may be more preliminary or opinion-based. The lack of a structured Q&A or panel discussion limits the opportunity for critical evaluation of the presented data. Overall, the symposium offers valuable insights into the future directions of pancreatic cancer research and therapy, but it is primarily intended for a specialized audience.

The title accurately reflects the content, which focuses on challenges and future perspectives in pancreatic cancer, specifically sessions III and IV of the symposium.

8/10

The video features presentations by leading researchers in pancreatic cancer, covering recent findings and clinical perspectives. The content is based on published research and ongoing clinical trials, with a high level of expertise. However, as a symposium, it may present some preliminary data and personal opinions.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction by session chair Andrés Muñoz Martín
• 03:00Peter Bailey begins talk on genetic and non-genetic mechanisms in PDAC
• 10:00Discussion of transcriptional subtypes and chemotherapy-induced plasticity
• 20:00Presentation of data on extrachromosomal DNA in pancreatic cancer
• 30:00Dieter Saur discusses tumor-host interactions
• 40:00Nuria Malats explores diabetes-obesity-pancreatic cancer axis
• 50:00Nelson Dusetti on molecular routes of resistance
• 1:00:00Session IV begins with Silvestre Vicent Cambra on KRAS inhibitor combinations
• 1:10:00Laura Soucek discusses targeting KRAS
• 1:20:00Teresa Macarulla reviews therapeutic options
• 1:30:00Ignacio Garrido-Laguna on targeting KRAS beyond G12C
• 1:40:00Closing remarks by Alfredo Carrato

• Genetic and non-genetic mechanisms driving progression and resistance to therapy in PDAC — Presentation by Peter Bailey, based on his published research.
• Tumor host interactions in pancreatic cancer — Presentation by Dieter Saur.
• Metabolic Crossroads: Exploring the Diabetes–Obesity–Pancreatic Cancer Axis — Presentation by Nuria Malats.
• Exploring the molecular routes of resistance in pancreatic cancer — Presentation by Nelson Dusetti.
• Combination strategies to potentiate the effect of KRAS inhibitors — Presentation by Silvestre Vicent Cambra.
• The long journey to inhibit an “undruggable” target in pancreatic cancer and beyond — Presentation by Laura Soucek.
• State of the art and new therapeutic options in advance pancreatic cancer — Presentation by Teresa Macarulla.
• Targeting KRAS beyond G12C — Presentation by Ignacio Garrido-Laguna.

• Pancreatic cancer research — NCI resources on pancreatic cancer research.